

Pursuant 37 C.F.R. 1.116, Applicant amends claim 9 to read as follows:

**IN THE CLAIMS:**

Amend Claim 9 to read:

9. An assay for determining the concentration of epidermal growth factor receptor in a biological sample from a human patient, the assay comprising:

- a) obtaining a biological sample from the patient;
  - b) contacting an amount of a first purified antibody that specifically reacts with a first epitope of the extracellular ligand binding domain of sErbB1 with the patient biological sample to be tested, wherein the first purified antibody is modified with a first labeling moiety;
  - c) contacting the sample with an amount of a second purified antibody that specifically reacts with a second epitope of the extracellular ligand binding domain of sErbB1, wherein the second purified antibody is modified with a second labeling moiety, and wherein the second purified antibody does not competitively inhibit the binding of the first purified antibody; and
  - d) detecting the co-presence of the first and second labels to determine the concentration of the epidermal growth factor receptor complexed with the antibodies;
- wherein one of the antibodies is chosen from the group consisting of: MAb R.1 and

antibodies which competitively inhibit the binding of MAb R.1 to ErbB1; and wherein the other antibody is chosen from the group consisting of MAb 528 and antibodies which competitively inhibit the binding of MAb 528 to ErbB1.